Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation

Sifei Xing, Cynthia K. Bullen, Neeta S. Shroff, Liang Shan, Hung Chih Yang, Jordyn L. Manucci, Shridhar Bhat, Hao Zhang, Joseph B. Margolick, Thomas C. Quinn, David M. Margolis, Janet D. Siliciano, Robert F. Siliciano

Research output: Contribution to journalArticlepeer-review

Abstract

Highly active antiretroviral therapy (HAART) can reduce plasma HIV-1 levels to below the detection limit. However, due to the latent reservoir in resting CD4+ cells, HAART is not curative. Elimination of this reservoir is critical to curing HIV-1 infection. Agents that reactivate latent HIV-1 through nonspecific T cell activation are toxic. Here we demonstrate in a primary CD4+ T cell model that the FDA-approved drug disulfiram reactivates latent HIV-1 without global T cell activation. The extent to which disulfiram reactivates latent HIV-1 in patient cells is unclear, but the drug alone or in combination may be useful in future eradication strategies.

Original languageEnglish (US)
Pages (from-to)6060-6064
Number of pages5
JournalJournal of virology
Volume85
Issue number12
DOIs
StatePublished - Jun 2011

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Fingerprint Dive into the research topics of 'Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation'. Together they form a unique fingerprint.

Cite this